What it sells
Cardiovascular AI
Business model breakdown
Buyer: who owns the budget?
UnverifiedCath lab / interventional cardiology leaders and radiation safety or hospital administrators (inferred).
Trigger: what makes them buy now?
Reducing radiation dose: halving cine frame rate (15 to 7.5 fps) halves the X-ray pulses but makes motion choppy, which is why labs keep 15 fps.
Workflow: what inputs become what output?
Angiography system acquires at 7.5 fps; study is sent via DICOM to an on-premise edge server running Angio-FILM, which detects contrast segments and generates in-between frames (2x or 4x); restored cine returns in near real time to the review monitor.
Economics: what it saves and how it charges
AI software (Angio-FILM, AF100) installed on a dedicated on-premise edge server; value is dose reduction without new X-ray equipment. Commercial terms not published.
Distribution: how it reaches customers
Pilot-led: "Discuss a pilot" CTA; vendor-neutral via DICOM, compatibility confirmed per site.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-15 | Seed | — | Kakao Ventures, SNU Holdings | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.